The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year



Acquired | Acquired

Total Raised




About Aspire Health

Aspire Health is a home and outpatient-based palliative care provider that operates a group of specialized physician practices that care for patients facing a serious illness.

Aspire Health Headquarter Location

333 Commerce St. Suite 700

Nashville, Tennessee, 37201,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aspire Health

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aspire Health is included in 2 Expert Collections, including Conference Exhibitors.


Conference Exhibitors

5,501 items

HLTH is a healthcare event bringing together startups and large companies from pharma, health insurance, business intelligence, and more to discuss the shifting landscape of healthcare


Value-Based Care & Population Health

860 items

The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.

Latest Aspire Health News

Hemostemix Announces Its Intellectual Property is Back Home

May 10, 2022

Calgary, Alberta--(Newsfile Corp. - May 10, 2022) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce it has settled all litigation with, and closed the settlement agreement with, Aspire Health Services, Inc., AJIA Global, LLC and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald Cooper, and Kingsman Scientific Management. Hemostemix is now in possession of all of its intellectual property, including all HS 12-01 Phase II clinical trail data, all historical data from Hemostemix Israel, and the randomization tables that are required to analyse the North American and South African ACP-01 clinical trial data. ABOUT HEMOSTEMIX Hemostemix is a publicly traded autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company developed and has published seven peer reviewed articles about the safety and efficacy of its lead product ACP-01 as a treatment of CLI, PAD, Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation. On October 21, 2019, the Company announced the results from its Phase II CLI trial abstract presentation entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83% of patients, with outcomes maintained for up to 4.5 years. The Company owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy. For more information, please visit . For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact included herein, are forward-looking information. In particular, this news release contains forward-looking information in relation to the return to Hemostemix of its intellectual property including all HS 12-01 phase II clinical trail data, all historical data from Hemostemix Israel, including the randomization tables that are required to analyse the North American and South African ACP-01 clinical trial data, the settlement of all outstanding litigation by and between Aspire Health Services, Inc., Accudate Solutions Inc., AJIA and Alan Jacobs, Jed Wood, Randi Wood, Blake Wood, Kyle Makofka, Reginald Cooper, Kingsman Scientific Management, and Hemostemix Inc. ‎‎There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the return to Hemostemix of all of its intellectual property and HS 12 - 01 Clinical Trial data and its impact to the underlying value of Hemostemix and its Common Shares; the successful settlement of all litigation (the "Litigation"); the embedded results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies as well as management's ‎expectations of anticipated results; Hemostemix's general and administrative costs remaining constant; the receipt of all required regulatory ‎approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the ‎economy generally; consumer ‎interest in Hemostemix's services and products; competition and ‎Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to ‎fund Hemostemix's operations including any research, trials or studies. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete its current CLI clinical trial, complete satisfactory analyses pf clinical trials and other information, and the results of such analyses and future clinical ‎trials; ‎litigation and potential litigation that Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation ‎affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete;‎ lack of qualified, skilled labour or loss of key individuals; and risks ‎related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to ‎try to limit the pandemic, including travel restrictions, border closures, non-essential business closures, ‎service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and ‎financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a ‎possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix ‎offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at . Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Sign up for Alerts Sign up to receive news releases by email for Hemostemix Inc. or all companies belonging to the Biotechnology, Pharmaceuticals, Health industries.

  • When was Aspire Health founded?

    Aspire Health was founded in 2011.

  • Where is Aspire Health's headquarters?

    Aspire Health's headquarters is located at 333 Commerce St., Nashville.

  • What is Aspire Health's latest funding round?

    Aspire Health's latest funding round is Acquired.

  • How much did Aspire Health raise?

    Aspire Health raised a total of $53.77M.

  • Who are the investors of Aspire Health?

    Investors of Aspire Health include Anthem, Sandbox Industries, Oak HC/FT Partners, Google Ventures, The Blue Venture Fund and 7 more.

  • Who are Aspire Health's competitors?

    Competitors of Aspire Health include CareCentrix.

You May Also Like

ViBo Health

ViBo Health enables users to track their health status using a quick and painless wrist scan and receive information on their direct and relevant metabolic measurements.

UniVita Health Logo
UniVita Health

Univita is the nationwide provider in home healthcare solutions. The company works collaboratively with health plans, health systems and physicians to improve quality and reduce hospital readmissions, while focusing on the health and well-being of patients in their homes. Its home care model delivers evidence based, high quality care for individuals, including Medicare, Medicaid and commercial plan members. The company offers a comprehensive home health program, which includes nursing and therapy services, durable medical equipment, infusion pharmacy services and its innovative Re-admission Reduction Solution.

eviCore Healthcare Logo
eviCore Healthcare

eviCore healthcare offers proven, diversified medical benefit management solutions that help clients reduce costs while increasing quality of care for their members. The company provides these solutions to managed care organizations and risk-bearing provider organizations serving commercial, Medicare and Medicaid populations. Powered by a team of specialized medical professional resources, extensive evidence-based guidelines and advanced technologies, the company supports clients by ensuring the right evidence-based care is delivered at the right time to the right patient at the right site of care. Flexible medical benefit management solutions are offered in: Diagnostic Testing and Imaging; Cardiology; Comprehensive Musculoskeletal and Pain Management; Medical and Radiation Oncology; Sleep Services; Lab Management; and Post-Acute Care (including participating in the CMS Bundled Payments for Care Improvement Initiative). eviCore is proud to help over 80 million Americans receive higher quality, lower cost healthcare.

myNEXUS Logo

myNEXUS acts as a link that connects many parts of the healthcare system including individuals, physicians, health providers, and insurers. myNEXUS's care management team focuses on reducing waste by managing care according to proven clinical criteria and business intelligence. For individuals with chronic conditions, the company uses a daily biometric monitoring system that allows them to detect, prevent and intervene at the appropriate times resulting in better outcomes, decreased re-hospitalizations, and lower costs.On March 24th, 2021, myNEXUS was acquired by Anthem. Terms of the transaction were not disclosed.

Signify Health Logo
Signify Health

Signify Health (NYSE: SGFY) partners with health plans, healthcare providers, biotechnology and pharmaceutical companies, and technology companies to provide tech-enabled care services to vulnerable populations.


NaviHealth partners with health plans, health systems and post-acute providers to manage the entire continuum of post-acute care. The company utilizes evidence-based protocols to optimize care and bundled payment methodologies to align all stakeholders.On May 19, 2020, NaviHealth was acquired by Optum. The terms of the transaction were not disclosed.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.